CymaBay Therapeutics, Inc. vs ACADIA Pharmaceuticals Inc.: SG&A Expense Trends

Biotech Giants: SG&A Expense Trends Unveiled

__timestampACADIA Pharmaceuticals Inc.CymaBay Therapeutics, Inc.
Wednesday, January 1, 2014327480008185000
Thursday, January 1, 2015908040008871000
Friday, January 1, 20161864560009645000
Sunday, January 1, 201725506200012387000
Monday, January 1, 201826575800014381000
Tuesday, January 1, 201932563800019238000
Wednesday, January 1, 202038866100017425000
Friday, January 1, 202139602800023040000
Saturday, January 1, 202236909000025116000
Sunday, January 1, 202340246600051953000
Loading chart...

Unleashing insights

SG&A Expense Trends: CymaBay vs. ACADIA

In the competitive landscape of biotechnology, understanding financial trends is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of CymaBay Therapeutics, Inc. and ACADIA Pharmaceuticals Inc. over the past decade. From 2014 to 2023, ACADIA's SG&A expenses surged by over 1,100%, peaking in 2023. In contrast, CymaBay's expenses grew by approximately 535% during the same period. This stark difference highlights ACADIA's aggressive expansion strategy compared to CymaBay's more conservative approach. Notably, ACADIA's expenses consistently outpaced CymaBay's, reflecting its larger operational scale. The data underscores the importance of strategic financial management in sustaining growth and competitiveness in the biotech sector. As the industry evolves, these trends offer valuable insights into the financial health and strategic priorities of these companies.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025